.avif)
NSE Test - Neuroendocrine Tumor Biomarker
Measures neuron‑specific enolase (NSE) in blood or CSF to help detect and monitor neuroendocrine tumors—most notably small‑cell lung cancer and neuroblastoma—as a tumor marker to guide treatment and follow‑up. It can also indicate neuronal injury after stroke, hypoxic brain damage or cardiac arrest, prompting earlier intervention to reduce long‑term neurologic complications.
Chromogranin A Test - Neuroendocrine Tumor Biomarker
Chromogranin A (CgA) testing helps detect and monitor neuroendocrine tumors (such as carcinoid tumors, pheochromocytoma, and medullary thyroid cancer) by measuring a protein released by these cells. Early detection or rising CgA levels can prompt timely follow-up and treatment, reducing the risk of tumor growth, spread, and related complications.
Pancreastatin Test - Neuroendocrine Tumor Biomarker
Pancreastatin is a blood biomarker used to detect and monitor neuroendocrine tumors and pancreatic endocrine dysfunction. Testing can pick up abnormal hormone-producing tumors earlier, helping guide treatment and reduce the risk of tumor progression and hormone-related complications.
5-HIAA Urine Test - Neuroendocrine Tumor Biomarker
A 5‑HIAA urine test measures the breakdown product of serotonin to screen for or monitor serotonin‑secreting carcinoid (neuroendocrine) tumors and related serotonin excess. Early detection can help prevent worsening carcinoid syndrome (flushing, diarrhea), tumor progression and complications such as carcinoid heart disease.
Chromogranin A Test - Neuroendocrine Tumor Biomarker
Chromogranin A (CgA) is a blood test that detects elevated levels of a neuroendocrine biomarker to help identify and monitor neuroendocrine tumors (e.g., carcinoid tumors, pheochromocytomas) and gauge treatment response. Early detection and monitoring can help prevent delayed diagnosis and complications from tumor growth or metastasis.
.svg)
